Low-Carbohydrate Nutrition Approaches in Patients with Obesity, Prediabetes and Type 2 Diabetes

Low Carb Nutritional Approaches - Guidelines Advisory

Issue link: https://eguideline.guidelinecentral.com/i/1180534

Contents of this Issue

Navigation

Page 11 of 15

12 Medication Management Figure 3. Follow-Up Diabetes Medication Changes Blood glucose range • Do not take bolus insulin at time of measurement • Decrease insulin 50% • Stop secretagogues Notes: • When reducing insulin, typically reduce bolus and basal insulins at same time with a goal to have basal insulin as ½ to ⅔ of total daily dose. • If no insulin or secretagogue in regimen and blood glucose <250 mg/dl, taper off thiazolidinedione (due to weight gain side effect) and try to lose weight. • If adding an agent, choose agents that are weight neutral or lead to weight loss: metformin, GLP-1 agonists. • Avoid alpha-glucosidase inhibitors (due to diminished efficacy with low- carbohydrate intake) and SGLT-2 inhibitors (to minimize risk of ketoacidosis). <100 mg/dL 100-149 mg/dL 150-249 mg/dL 250-299 mg/dL ≥300 mg/dL • Decrease insulin 50% • Stop secretagogues • If weight stable: no changes. • If losing weight: decrease insulin 25-50% • Stop secretagogues • If weight stable: add agent • If losing weight: decrease insulin 10-25% • Stop secretagogues • If weight stable: add agent • If losing weight: no changes or add agent

Articles in this issue

view archives of Low-Carbohydrate Nutrition Approaches in Patients with Obesity, Prediabetes and Type 2 Diabetes - Low Carb Nutritional Approaches - Guidelines Advisory